Third Rock Ventures Launches SAGE Therapeutics

Third Rock Ventures has launched SAGE Therapeutics with a $35 million Series A financing. SAGE's efforts focus on advancing a pipeline of new, critically needed treatments for some of the most disabling central nervous system (CNS) disorders such as schizophrenia, depression, pain and traumatic brain injury (TBI).

North AmericaUSBriefs